Literature DB >> 29661831

Differential Effects of Estrogen Receptor β Isoforms on Glioblastoma Progression.

Jinyou Liu1,2, Gangadhara R Sareddy1,3, Mei Zhou1,4, Suryavathi Viswanadhapalli1, Xiaonan Li1, Zhao Lai5, Rajeshwar R Tekmal1,3, Andrew Brenner3,6, Ratna K Vadlamudi7,3.   

Abstract

The estrogen receptor β (ERβ) functions as a tumor suppressor in glioblastoma (GBM) cells. However, the in vivo significance of endogenous ERβ and the roles of its isoforms in GBM are incompletely understood. Using ERβ isoform-specific PCR screening, we found that GBM cells predominantly express ERβ1 and ERβ5, along with low levels of ERβ2 and ERβ4. We observed greater ERβ5 expression in higher grades of glioma than in lower grades. In CRISPR-based ERβ knockout (KO) cells and ERβ KO cells uniquely expressing ERβ1 or ERβ5 only, ERβ1 significantly reduced proliferation. Compared with parental GBM cells, ERβ KO cells exhibited high migratory and invasive potentials, and reexpression of ERβ1 resulted in the reduction of this phenotype. Interestingly, ERβ5 expression increased foci formation and anchorage-independent growth of NIH3T3 cells and increased motile structure formation, including filopodia and ruffles in GBM cells. Only ERβ1-expressing tumors resulted in longer mouse survival. RNA-Seq analysis revealed unique pathways modulated by ERβ1 and ERβ5. Compared with ERβ KO cells, ERβ1 cells exhibited lower activation of mTOR signaling molecules, including p-mTOR, p-S6K, and p-S6, and ERβ5-expressing cells had enhanced mTOR downstream signaling. Unique proteins including several that function as regulators of mTOR, immunomodulatory, and apoptosis pathways bound to ERβ1 and ERβ5 isoforms. Our work confirms the tumor-suppressive potential of ERβ1 and reveals the acquired oncogenic ability of ERβ5 in GBM cells. ERβ isoform status and their unique interactions with oncogenic pathways may have important implications in GBM progression.Significance: These findings suggest that only ERβ isoform 1 has tumor suppressor function in GBM and that ERβ isoform switching contributes to GBM progression. Cancer Res; 78(12); 3176-89. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29661831      PMCID: PMC6004261          DOI: 10.1158/0008-5472.CAN-17-3470

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  60 in total

1.  Differential expression of estrogen receptor beta isoforms in prostate cancer through interplay between transcriptional and translational regulation.

Authors:  Ming-Tsung Lee; Bin Ouyang; Shuk-Mei Ho; Yuet-Kin Leung
Journal:  Mol Cell Endocrinol       Date:  2013-06-24       Impact factor: 4.102

Review 2.  Estrogen receptors: therapies targeted to receptor subtypes.

Authors:  S Nilsson; J-Å Gustafsson
Journal:  Clin Pharmacol Ther       Date:  2010-12-01       Impact factor: 6.875

3.  Frequent loss of estrogen receptor-beta expression in prostate cancer.

Authors:  L G Horvath; S M Henshall; C S Lee; D R Head; D I Quinn; S Makela; W Delprado; D Golovsky; P C Brenner; G O'Neill; R Kooner; P D Stricker; J J Grygiel; J A Gustafsson; R L Sutherland
Journal:  Cancer Res       Date:  2001-07-15       Impact factor: 12.701

4.  Hormone receptor expression profile of low-grade serous ovarian cancers.

Authors:  Marianna Buttarelli; Floriana Mascilini; Gian Franco Zannoni; Alessandra Ciucci; Enrica Martinelli; Flavia Filippetti; Giovanni Scambia; Gabriella Ferrandina; Daniela Gallo
Journal:  Gynecol Oncol       Date:  2017-02-20       Impact factor: 5.482

5.  The expression of estrogen receptors β2, 5 identifies and is associated with prognosis in non-small cell lung cancer.

Authors:  Zhaoguo Liu; Yongde Liao; Hexiao Tang; Guang Chen
Journal:  Endocrine       Date:  2013-03-10       Impact factor: 3.633

6.  Involvement of estrogen receptor β5 in the progression of glioma.

Authors:  Wenjun Li; Ali Winters; Ethan Poteet; Myoung-Gwi Ryou; Song Lin; Shuyu Hao; Zhen Wu; Fang Yuan; Kimmo J Hatanpaa; James W Simpkins; Shao-Hua Yang
Journal:  Brain Res       Date:  2013-02-08       Impact factor: 3.252

Review 7.  Insight into the mechanisms of action of estrogen receptor β in the breast, prostate, colon, and CNS.

Authors:  Prasenjit Dey; Rodrigo P A Barros; Margaret Warner; Anders Ström; Jan-Åke Gustafsson
Journal:  J Mol Endocrinol       Date:  2013-11-26       Impact factor: 5.098

8.  Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor.

Authors:  Rajib Rajhans; Sujit Nair; Alan H Holden; Rakesh Kumar; Rajeshwar Rao Tekmal; Ratna K Vadlamudi
Journal:  Cancer Res       Date:  2007-06-01       Impact factor: 12.701

9.  Estrogen Receptor β2 Induces Hypoxia Signature of Gene Expression by Stabilizing HIF-1α in Prostate Cancer.

Authors:  Prasenjit Dey; Laura A Velazquez-Villegas; Michelle Faria; Anthony Turner; Philp Jonsson; Paul Webb; Cecilia Williams; Jan-Åke Gustafsson; Anders M Ström
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

10.  Agonists and knockdown of estrogen receptor β differentially affect invasion of triple-negative breast cancer cells in vitro.

Authors:  Susanne Schüler-Toprak; Julia Häring; Elisabeth C Inwald; Christoph Moehle; Olaf Ortmann; Oliver Treeck
Journal:  BMC Cancer       Date:  2016-12-21       Impact factor: 4.430

View more
  27 in total

1.  PELP1 signaling contributes to medulloblastoma progression by regulating the NF-κB pathway.

Authors:  Yiliao Luo; Mengxing Li; Uday P Pratap; Suryavathi Viswanadhapalli; Junhao Liu; Prabhakar P Venkata; Kristin A Altwegg; Bridgitte E Palacios; Xiaonan Li; Yihong Chen; Manjeet K Rao; Andrew J Brenner; Gangadhara R Sareddy; Ratna K Vadlamudi
Journal:  Mol Carcinog       Date:  2019-12-24       Impact factor: 4.784

2.  Inhibition of Hyaluronic Acid Synthesis Decreases Endometrial Cell Attachment, Migration, and Invasion.

Authors:  Jessica E McLaughlin; Marlen Tellez Santos; Peter A Binkley; Mubeen Sultana; Rajeshwar R Tekmal; Robert S Schenken; Jennifer F Knudtson
Journal:  Reprod Sci       Date:  2020-02-03       Impact factor: 3.060

3.  Hormone exposure and its suppressive effect on risk of high-grade gliomas among patients with breast cancer.

Authors:  Carlos A Lopez-Garcia; Victor Lopez-Rivera; Antonio Dono; Sergio Salazar-Marioni; Jorge E Novo; Sunil A Sheth; Leomar Y Ballester; Yoshua Esquenazi
Journal:  J Clin Neurosci       Date:  2021-11-02       Impact factor: 2.116

4.  Targeting Several Biologically Reported Targets of Glioblastoma Multiforme by Assaying 2D and 3D Cultured Cells.

Authors:  Yudibeth Sixto-López; Emilie Marhuenda; Juan Benjamin García-Vazquez; Manuel Jonathan Fragoso-Vazquez; Martha Cecilia Rosales-Hernández; Oscar Zacarías-Lara; David Méndez-Luna; José Antonio Gómez-Vidal; David Cornu; Bakalara Norbert; José Correa-Basurto
Journal:  Cell Mol Neurobiol       Date:  2021-03-19       Impact factor: 5.046

Review 5.  The genomic architecture of metastasis in breast cancer: focus on mechanistic aspects, signalling pathways and therapeutic strategies.

Authors:  Yogita Chhichholiya; Prabhat Suman; Sandeep Singh; Anjana Munshi
Journal:  Med Oncol       Date:  2021-07-16       Impact factor: 3.064

6.  Contrasting activities of estrogen receptor beta isoforms in triple negative breast cancer.

Authors:  Shunchao Yan; Parama Dey; Yvonne Ziegler; Xin Jiao; Sung Hoon Kim; John A Katzenellenbogen; Benita S Katzenellenbogen
Journal:  Breast Cancer Res Treat       Date:  2020-10-01       Impact factor: 4.872

7.  Estradiol Regulates mRNA Levels of Estrogen Receptor Beta 4 and Beta 5 Isoforms and Modulates Human Granulosa Cell Apoptosis.

Authors:  Alice Pierre; Anne Mayeur; Clémentine Marie; Victoria Cluzet; Jonathan Chauvin; Nelly Frydman; Michael Grynberg; Joelle Cohen-Tannoudji; Céline J Guigon; Stéphanie Chauvin
Journal:  Int J Mol Sci       Date:  2021-05-10       Impact factor: 5.923

Review 8.  Our evolving understanding of how 27-hydroxycholesterol influences cancer.

Authors:  Liqian Ma; Wonhwa Cho; Erik R Nelson
Journal:  Biochem Pharmacol       Date:  2021-05-24       Impact factor: 5.858

Review 9.  Mechanisms for estrogen receptor expression in human cancer.

Authors:  Hui Hua; Hongying Zhang; Qingbin Kong; Yangfu Jiang
Journal:  Exp Hematol Oncol       Date:  2018-09-19

10.  HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells.

Authors:  Belinda J Petri; Kellianne M Piell; Gordon C South Whitt; Ali E Wilt; Claire C Poulton; Norman L Lehman; Brian F Clem; Matthew A Nystoriak; Marcin Wysoczynski; Carolyn M Klinge
Journal:  Cancer Lett       Date:  2021-07-14       Impact factor: 9.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.